Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Macrophage monocarboxylate transporter 1 promotes peripheral nerve regeneration after injury in mice
All clinical trials must be approved and continuously monitored by an independent Institutional Review Board or a Human Rights Committee
Afamelanotide was approved by the European Medicines Agency in 2014 under the brand name Scenesse for the prevention of phototoxicity in patients with erythropoietic protoporphyria
pylori in humans
Potential Side Effects and Safety Concerns Although the treatment is safe in medically supervised settings, mild side effects can happen, such as: Temporary redness or swelling at the injection site Slight dizziness or nausea Rare allergic reactions (rash, itching) Patients are advised to disclose any history of allergies or chronic illness before starting treatment
Doing so could lead to serious injury and infections
US$ 28.11
US$ 24.83
US$ 21.93
US$ 22.00
